Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in advanced NSCLC
NCT03085069Phase 2Unknown
- Sponsor
- Hengrui
- Start
- May 2017
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03085069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085069.